Acute and Chronic Leukemias

Expert faculty review and share their insights and perspectives on key findings in acute and chronic leukemias presented at the 2022 ASH Annual Meeting.

Share

Program Content

Activities

  • ASH 2022 Leukemia Highlights
    Key Studies in Leukemias: Independent Conference Coverage of ASH 2022
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 21, 2023

    Expires: March 20, 2024

Activities

V-FAST FLT3 Subgroup
V-FAST Subgroup Analysis: CPX-351 + Midostaurin in Newly Diagnosed AML by FLT3 Mutation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

GRAALL-2014/B QUEST
GRAALL-2014/B Quest Cohort Analysis: Blinatumomab During Consolidation in Adults With High-Risk Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

GMALL-INITIAL1
GMALL-INITIAL1: Inotuzumab Ozogamicin Induction Therapy Followed by Standard Chemotherapy in Older Patients With B-Lymphoblastic Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

VIALE-A Extended Follow-up
VIALE-A: Extended Follow-up of Azacitidine ± Venetoclax in Patients With Treatment-Naive AML Ineligible for Standard Induction Chemotherapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

PhI/II AZA/VEN/MAG
Phase I/II Trial of Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Low-Dose Dasatinib in CML
Low-Dose Dasatinib for Newly Diagnosed CML: Long-term Follow-up Outcomes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

AUGMENT-101: Revumenib
AUGMENT-101: Phase I Study of Revumenib in Patients With KMT2A-Rearranged or NPM1-Mutant AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

Ziftomenib in AML
Phase I/II KOMET-001: First-in-Human Study of Ziftomenib, a Novel KMT2A-Menin Inhibitor, in Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2022

Expires: December 11, 2023

ASC4MORE: Addition of Asciminib to Imatinib
ASC4MORE: Phase II Trial of Addition of Asciminib to Imatinib vs Continued Imatinib vs Switch to Nilotinib in Patients With Chronic-Phase CML Not Achieving Deep Molecular Responses With ≥1 Yr of Imatinib Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

Gilteritinib/Aza/Ven/ in <em>FLT3</em>-Mut AML
Phase I/II Trial of Triplet Combination of Gilteritinib + Azacitidine/Venetoclax in Patients With FLT3-Mutated AML: Updated Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

ECOG-ACRIN E1910
ECOG-ACRIN E1910: Phase III Study of Consolidation Chemotherapy ± Blinatumomab in MRD-Negative BCR::ABL1-Negative B-ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

Faculty

cover img faculity

Amir T. Fathi, MD

Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen